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ABSTRACT
Objective: Ewing Sarcoma Family of Tumors (ESFT) are a highly aggressive pediatric bone and soft tissue malignancy with poor outcomes in
the refractory and recurrent setting. Over 90% of Ewing Sarcoma (ES) tumors are driven by the pathognomonic EWS-ETS chimeric transcripts
and their corresponding oncoproteins. It has been suggested that the EWS-ETS oncogenic action can mediate microRNA (miRNA) processing.
Importantly, small extracellular vesicles (sEVs), including those frequently referred to as exosomes have been shown to be highly enriched with
tumor-derived small RNAs such as miRNAs. We hypothesized that ESFT-specific sEVs are enriched with certain miRNAs which could be utilized
toward an exo-miRNA biomarker signature specific to this disease.
Methods: We performed miRNAseq to compare both the exo-derived and cell-derived miRNA content from 8 ESFT, 2 osteosarcoma, 2 noncancerous cell lines, and pediatric plasma samples.
Results: We found that sEVs derived from ESFT cells contained nearly 2-fold more number of unique individual miRNAs as compared to nonESFT samples. Quantitative analysis of the differential enrichment of sEV miRNAs resulted in the identification of 62 sEV-miRNAs (exo-miRNAs)
with significant (P < .05) enrichment variation between ESFT and non-ESFT sEV samples. To determine if we could utilize this miRNA signature
to diagnose ESFT patients via a liquid biopsy, we analyzed the RNA content of total circulating sEVs isolated from 500 µL plasma from 5 pediatric ESFT patients, 2 pediatric osteosarcoma patients, 2 pediatric rhabdomyosarcoma patients, and 4 non-cancer pediatric controls. Pearson’s
clustering of 60 of the 62 candidate exo-miRNAs correctly identified 80% (4 of 5) of pathology confirmed ESFT patients. Importantly, RNAseq
analysis of tumor tissue from the 1 outlier, revealed a previously uncharacterized EWS-FLI1 translocation.
Conclusions: Taken together, these findings support the development and validation of an exo-miRNA-based liquid biopsy to aid in the
diagnosis and monitoring of ESFT.
Keywords: Small extracellular vesicles, exosomes, Ewing Sarcoma, Ewing Sarcoma Family of Tumors, microRNA, exo-miRNAs, biomarkers, liquid biopsy, EWS-FLI1 fusions
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Introduction

Collectively, ESFT is characterized and largely driven by a family
of chromosomal translocations which result in a chimeric transcription factor combining the N-terminal, transcriptional activation domain of the EWSR1 gene with the C-terminal, DNA
binding domain of one of several members of the ETS family of
transcription factors such as FLI1 and ERG.2,3 In over 90% of
ESFT cases, the fusion occurs at t(11,22)(q24;q12), resulting in
the EWS-FLI1 oncoprotein. An additional form of molecular

The Ewing Sarcoma Family of Tumors (ESFT) are the second
most common pediatric bone and soft tissue malignancies after
osteosarcoma and primarily affect children and young adults in
their second decade of life. The disease encompasses a family of
tumors believed to derive from the same cell type consisting of
osseous Ewing sarcoma, extraosseous Ewing sarcoma, peripheral
primitive neuroectodermal tumors (PNET), and Askin tumors.1
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genetic heterogeneity stems from the location of translocation
breakpoints resulting in inclusion of different exon combinations
from EWSR1 and FLI1 within the fusion products, with the
most commonly occurring Type I followed by Type II.4 The second most abundant translocation after those involving FLI1
occurs at t(21;22)(q22;q12) resulting in the EWS-ERG oncoprotein. A small fraction (<5%) of ESFT patients will have
EWSR1 fusions with ETV1, ETV4, or FEV. Detection of translocation presence are typically clinically identified by Florescent
In Situ Hybridization (FISH) assay directed at the 3′ and 5′ ends
of the EWSR1 gene in samples collected through diagnostic
tumor tissue biopsy. Tumor tissue is also used to evaluate the
small, round blue cell morphology of ESFT tumors and immunohistology conducted to measure membranous CD99 (MIC2)
staining which is nonspecific but highly expressed in ESFT.
Given a lack of additional biomarkers, the current methods of
disease diagnosis, monitoring, and progression are limited to
invasive biopsies and radiation exposure via imaging modalities,
such as X-rays, computed tomography scan, magnetic resonance
imaging, bone scan, and fluoride-18 fluorodesoxyglucose positron
emission tomography. Presently, there remains an unmet need for
the development of complementary methodologies toward rapid
and specific diagnosis and monitoring of ESFT.
A primary function of the EWS-ETS oncoprotein is transcriptional regulation. In addition to this, a large body of work
has demonstrated that EWS-ETS can also act to regulate
microRNA (miRNA), synthesis through a combination of
aberrant transcription regulation and association with miRNA
processing machinery leading to a handful of publications on
ESFT cellular miRNA biomarkers.5,6 miRNAs are a class of
small, non-coding RNAs between 18 and 24 nucleotides which
act as translational repressors by binding to the 3′ untranslated
region (UTR) of target gene mRNAs. To date, over 1500
human miRNAs have been identified, each of which can regulate a few to hundreds of mRNAs.7 miRNAs are an essential
regulatory mechanism in normal physiology and are frequently
dysregulated in pathological states such as cancer. Specifically,
miRNAs have been shown to be involved in most recognized
pathways of tumorigenesis, including immune suppression,
angiogenesis, metastasis, and drug resistance. Importantly, miRNAs can be transferred from cell-to-cell via subsets of sEVs
which are from the endosomal system and are commonly
referred to as exosomes.8,9 miRNA-sorting into sEVs appears to
be a tightly regulated, albeit elusive process with a variety of
miRNAs commonly found within sEVs and others almost
never enriched into these vesicles.10,11 Although sEVs are produced by nearly all types of healthy cells, sEV production is dramatically elevated in pathological states such as cancer.12
Importantly, these vesicles have been shown to be readily isolated from nearly all forms of bodily fluids including whole
blood, serum, and plasma.
Given that ESFT tumors harbor unique miRNA profiles and
the fact that some miRNAs can be enriched within sEVs, we

hypothesized that miRNA content analysis of ESFT cell lines
and their corresponding sEVs may reveal a miRNA signature
which could be beneficial toward diagnosis and monitoring of
ESFT disease clinical status (regression, progression, and recurrence). To test this hypothesis, we conducted miRNA sequencing
of 8 ESFT cell lines and their derived sEVs representing the
most clinically relevant EWS-ETS fusions to develop an exomiRNA signature. We then performed a preliminary evaluation
on rare clinical ESFT patient plasma-derived sEVs and were able
to identify 4 out of 5 ESFT patients successfully. Interestingly,
the single ESFT patient not identified via this exo-miRNA signature carried a rare, previously uncharacterized EWS-FLI1
translocation. Together these data provide the framework for
development of a blood-based assay capable of both detecting
and monitoring the majority of ESFT tumor types.

Methods
Cell line and culture conditions
Hs919.T, SK-ES-1, RD-ES were purchased from the
American Type Culture Collection. TC-32, TC-71, COG-E352, CHLA-32, CHLA-9, and CHLA-258 cell lines were
obtained from the Children’s Oncology Group (COG). F303
was previously generated in the Godwin laboratory.13 U2OS
and MG-63 were a kind gift of Dr. Tomoo Iwakuma (University
of Kansas Medical Center). All cell lines were cultured at 37°C
under a 5% humidified CO2 atmosphere. TC-71, TC-32,
CHLA-9, CHLA-32, COG-E-352, and CHLA-258 cell
lines were maintained in Iscove’s Modified Dulbecco’s Medium
(IMDM), supplemented with 3 mM L-glutamine, 5 mg/ml
insulin and transferrin, 5 ng/ml selenium, and 20% exosome
free FBS. RD-ES cell line was maintained in RPMI 1640 with
L-glutamine, supplemented with 15% exosome free FBS.
SK-ES-1 and MG-63 were maintained in McCoy’s 5A with
L-glutamine supplemented with 15% exosome free FBS
(whole medium). Hs919.T and U2OS cells were maintained in
DMEM with high glucose with L-glutamine, supplemented
with 20% exosome free FBS. Ten percent penicillin streptomycin was added to all medium.

SEV isolation
sEVs were isolated by differential ultracentrifugation as previously published.14 Briefly, conditioned media was collected
every 24 hours while cells were between 60% and 90% confluency. Media was centrifuged at 2500 rpm for 5 minutes to eliminate cellular debris. The media was then ultra-centrifuged
using a FIBERLite F40L rotor (Thermo Scientific) at 4°C for
45 minutes at 10 000g to pellet larger microvesicles. The supernatant was collected, transferred to new tubes and ultra-centrifuged for 60 minutes at 110 000g to pellet sEVs. sEVs were
resuspended in cold PBS, pooled together, and then spun once
more at 110 000g. sEV pellets were resuspended with an appropriate volume of PBS (50-200 µL) and stored at −80°C.
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Nanoparticle tracking analysis (NTA)
The NanoSight LM10 (NanoSight Ltd., Minton Park,
Amesbury, UK) was used to determine particle count and size
distribution of sEV samples by analyzing the Brownian Motion
of aliquots of sEVs diluted in PBS. Five measurements were
taken for each sample and the mean values were reported.

SDS-PAGE and western blot analysis
Cellular lysates were prepared in RIPA buffer (Thermo Fisher
Scientific) and sonicated. Forty microgram of cellular lysates or
sEV preparations were separated using Mini-PROTEAN®
TGX™ Precast Gels (BioRad) and then transferred to a supported nitrocellulose membrane (BioRad). Primary antibodies
for CD81 (mouse monoclonal antibody, clone D5O2Q), CD49
(Mouse monoclonal antibody, D9M81), Flotillin (Rabbit XP
monoclonal antibody, clone D2V7J), Alix (Mouse monoclonal
antibody, clone 3A9), and CD9 (mouse monoclonal antibody
clone D3H4P) were all from Cell Signaling Technology. ß-actin
(mouse monoclonal clone AC-15) was from Sigma Aldrich.
Anti-rabbit and anti-mouse secondary HRP conjugated antibodies were from Cell Signaling. All antibodies were diluted in
either 5% NFM or BSA in TBS according to manufactures
recommendations.

RNA isolation
To evaluate miRNAs carried in ESFT-derived EVs (sEVmiRNAs or exo-miRNAs) total RNA was isolated from sEVs
obtained from cell culture conditioned media by differential
ultracentrifugation (described above). sEVs (~50 µg of total
protein) were suspended in a small volume of PBS (<50 µL)
and were then lysed using the miRNeasy kit (Qiagen) following the manufacturer’s protocol for total RNA.
For plasma derived sEVs, peripheral blood was collected in
ACD tubes. The blood samples were centrifuged @ 1200g for
12 minutes at 4°C. Without disturbing the buffy coat, plasma
from 2 ACD tubes (~6 mL) were combined into a 15 mL falcon
tube and the samples were centrifuged at 2500g for 15 minutes at
4°C to remove debris and platelets. Once complete, plasma/
supernatant, carefully avoiding the pellet, was pipetted into a
new 15 mL falcon tube and the samples underwent a final spin
at 2500g for 15 minutes at 4°C. All plasma samples were stored
at −80°C until sEV purification and RNA isolation. We isolated
total RNA from sEVs using the manufacturer protocol with
500 µL plasma and the Qiagen Exo-RNeasy kit. This kit collects
all sEVs onto a membrane and directly lyses them resulting in
total RNA. All RNA samples were analyzed using the Pico 6000
chip on the Agilent bioanalyzer or the Nanoquant plate (Tecan).

MiRNA next generation sequencing
Isolated miRNA samples were prepared for next generation
sequencing using the Bioo Scientific, NEXTflex small RNA
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Seq v3 kit according to manufacturer’s protocols (Bioo
Scientific, Austin, TX). Briefly, 200 ng of isolated miRNA was
used for library preparation with 20 cycles of PCR amplification. Size selection was completed using a BluePippin (SAGE
Science, Beverly, MA). A 3% gel was used with a selected size
range of 135 to 185 base pairs. Samples were pooled for
sequencing on an Illumina MiSeq using v3 chemistry (1 × 35 bp
read) to a minimum of 700 K reads/sample after trimming.

MiRNA analysis
Single-end sequencing reads were trimmed to remove the
NEXTflex adapter and then processed with mirdeep2 v2.0.0.8.
First, trimmed reads were collapsed using the mirdeep2 “mapper.pl” script with the following parameters: -e -h -j -m -l 18.
Next, the collapsed reads were quantified against miRBase
release 22 using the mirdeep2 “quantifier.pl” script with the following parameters: -t hsa -d -W -p hairpin.fa -m mature.fa.
Resulting read counts for each miRNA were normalized by
total count scaling.15
Availability of data and material: Upon publication all data
sets will be made available in GEO, NCBI.

Tet-inducible knock-down
HEK293 T cells were plated in 10 cm dishes and allowed to
adhere overnight. The next day cells were transfected according
using Lipofectamine 3000 (Thermo Fisher), 1 µg pMD2.G
(Addgene #12259), 2 µg/L psPAX.2 (Addgene #12260), 3 µg
control shRNA or targeting shRNA plasmid. We used the Tetplko-puro-Scrambled plasmid as a non-targeting control
(Addgene #47541) and the Tet-pLKO-puro plasmid (Addgene
#21915) with the previously published FLI1 targeting sequence
5′ CGTCATGTTCTGGTTTGAGAT 3′. Viral particles were
collected 2 days post transfection and transferred to 50 mL tubes.
Tubes were spun at 200g for 5 minutes, filtered through a 0.4 µm
syringe filter, and transferred to 13 mL ultracentrifuge tubes and
spun at 120 000g for 1.5 hours. Supernatant was poured off and
the viral particles were allowed to dry for 2 minutes before being
dissolved in 100 µL of PBS and stored at −80°C.
ESFT cells were treated with 18 µg/ml Polybrene (Thermo
Fisher), and 10 µL viral concentrate. Cells were selected using
Puromycin in concentrations ranging from 0.5 to 1.0 µg/mL.
ESFT cells were treated with Doxycycline 48 hours prior to
sEV collection and then allowed to “rest” for 2 days. This cycle
was repeated to obtain sEVs under EWS-FLI1 knock-down
conditions.

Nanostring
Biological replicates of total RNA were pooled together. We
utilized the nCounter Human v3 miRNA panel on the
NCOUNTER FLEX following the manufacturers recommended protocol. Around 31 and 100 ng of total RNA were
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added for sEV and cell lysate preparations respectively. Results
were normalized by total count scaling and positive hits were
determined for values above the average of 5 individual negative controls.
Availability of data and material: Upon publication all data
sets will be made available in GEO, NCBI.

QRT-PCR analysis
Total RNA was reverse transcribed using the TaqMan®
Advanced miRNA cDNA synthesis Kit (Invitrogen) according
to manufactures instructions. All PCR were performed using
TaqMan® Advanced miRNA assays (Invitrogen). qPCR was
done utilizing triplicate samples on a BioRad CFX 96 real time
instrument (BioRad). Due to a lack of standardized normalization controls for sEV miRNA, we utilized the sequencing data
to select 3 miRNAs for normalization. First, we calculated the
average counts of each miRNA in each sample set. The samples were then ranked and samples with an average count >1
were selected. From this set we divided the standard deviation
by the average to generate a % of variance from the average. Of
these, 3 miRNAs were selected to have the highest expression
in samples with the least amount of variance from the mean;
Let-7a-5p, miR-143-3p, and miR-103a-3p. These miRNAs
were used together to normalize all cell-line derived sEV PCR
results.

EWSR1 fusion analysis
RNA/DNA next-generation sequencing panel. Genomic DNA
and RNA are extracted from manually macro dissected formalin-fixed paraffin-embedded (FFPE) tissue samples using AllPrep DNA/RNA FFPE kit (Qiagen). Following the library
preparation by targeted enrichment using a custom Qiagen
multimodal panel kit the sample was subjected to NGS to generate FASTQ files (text-based format for storing nucleotide
sequences). This assay is a targeted custom NGS Panel that
encompasses 486 genes with variable full exon or partial region,
27 MSI loci, and 574 fusions.
Bioinformatics. Data analyses for RNA fusions were performed
using QIAGEN’s CLC Genomics Workbench (version 20.0)
with manufacturer-recommended settings. The Unique
Molecular Index (UMI) reads were trimmed off while retaining the UMI information as an annotation on the read. The
trimmed reads were then mapped to the reference transcriptome sequence, and reads were grouped according to their
UMI. The fusion events identified were based primarily on the
number of fusion crossing reads, and on the number of fusion
spanning reads. The fusions detected were then refined. Only
the fusions meeting the manufacturer-recommended thresholds were reported: breakpoint distance 10, error rate 0.001,
minimum number of supporting reads 2, and maximum
P-value .005.

Statistical analysis
Pair wise comparison was performed between groups of interest. In brief, the Bioconductor package “edgeR” was used to
preprocess the raw miRNA count data. The data were normalized by library size. For downstream analysis, we only kept
genes with >1 cpm in more than or equal to 2 samples out of
47. As a result, a total of 1272 miRNAs were considered for
subsequent statistical analysis.
Clinical sample size was limited to the number of pediatric
plasma samples available to us and therefore, no power analysis
was performed. As an alternative we performed an unsupervised model-based clustering of the 46 miRNAs identified in
the clinical samples using a finite mixture of Gaussian distributions and assuming 2 clusters.

Results
ESFT cells release vesicles characterized as small
extracellular vesicles
We began by isolating sEVs from 8 ESFT cell lines representing the most common EWS-ETS fusions; CHLA-32,
CHLA-9, TC-32, TC-71 (EWS-FLI1 Type I); SK-ES-1,
RD-ES (EWS-FLI1 Type II); CHLA-258 (EWS-FLI1 Type
III) and COG-E-352 (EWS-ERG); as well as from 2 osteosarcoma cell lines MG-63 and U2OS; a benign osteoid
osteoma cell line Hs919.T, and a stromal cell line F303
(Table 1). sEVs were isolated via ultracentrifugation as previously published.16,17 We then subsequently lysed and separated the cellular and sEV proteomic content by SDS page.
sEVs were shown to have presence of one or more of common exosomal markers, for example, CD81, Flotillin, ALIX,
and CD9 (Supplemental Figure 1).18 A separate aliquot of
sEVs were diluted and analyzed for particle size using the
NanoSight LX. sEVs consistently averaged <200 nm in
diameter with a distribution of ~40 to 300 nm, which is characteristic of this population of small vesicles19 (Supplemental
Figure 2). Taken together this result indicates that the vesicles isolated for analysis are consistent with the population of
sEVs which contain exosomes.

ESFT sEVs contain a larger, more diverse
population of miRNA than non-ESFT sEVs
To evaluate miRNA expression in cells and enrichment
within sEVs, we isolated total RNA from biological replicates
of 8 ESFT and 4 control cell lines and 50 µg of their corresponding sEVs (Table 1). Next generation small RNA
sequencing was performed on each sample. In total, we identified a range of 586 to 1021 miRNAs in cells and 151 to 592
miRNAs in their corresponding sEVs (Figure 1A–D,
Supplemental Data Files). There was an increase (albeit not
significant) in the mean number of individual miRNAs identified between ESFT and non-ESFT cell lines (Figure 1A
and B). However, there was a significant increase (>2-fold;
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Table 1. Experimental cell lines.
Cell line

Sex

Age

Disease

Phase

Location

Chemo

CHLA-9

F

14y

PNET
EWS-FLI1 Type I

Primary

Thoracic

Pre

CHLA-32

F

8y

PNET
EWS-FLI1 Type I

Primary

Pelvic

Pre

TC-32

F

17y

PNET
EWS-FLI1 Type I

Primary

Ileum and adjacent soft
tissue

Pre

TC-71

M

22y

ES
EWS-FLI1 Type I

Recurrence/metastatic at
diagnosis

Recurrence in Humerus

Post

RD-ES

M

19y

ES
EWS-FLI1 Type II

Primary

Humerus

NA

SK-ES-1

M

18y

ES
EWS-FLI1 Type II

NA

NA

NA

CHLA-258

F

14y

PNET
EWS-FLI1 Type III

NA

Lung Metastasis

Post

COG-E-352

M

17y

PNET
EWS-ERG

Refractory disease

Peripheral blood. Postmortem (fibula primary)

Post

F303

F

NA

-

-

NA

-

Hs919.t

F

34y

Benign Osteoid Osteoma

-

Bone

-

MG-63

M

14y

Osteosarcoma

NA

NA

NA

U2OS

F

15y

Osteosarcoma

NA

Tibia

NA

PNET – Primitive neuroectodermal tumor, ES – Ewing Sarcoma, F-Female, M-Male, NA-Not available, Pre-Prior to Chemotherapy, Post – After Chemotherapy, ‘-’- Not
relevant

P = .0122) in the mean number of miRNAs detected within
the ESFT-sEVs versus non-ESFT-sEVs (mean values of 440
and 228 miRNAs, respectively) (Figure 1C and D).
Quantification of the total RNA from biological replicates of
the 8 ESFT and 4 Non-ESFT sEV samples (50 µg each)
indicated there was a slight, but not significant, increase in
the amount of total RNA isolated in ESFT-sEV samples as
compared to non-ESFT-sEV controls (Table 1 and Figure
1E). These results demonstrate that ESFT-sEVs possess an
increased number of individual, unique miRNAs.
Given the increased number of individual unique miRNAs
within the ESFT sEVs, we questioned what percentage of
parental cellular miRNAs were being enriched into their corresponding sEVs. To answer this, we quantified the miRNA
identified only in cellular lysates, only in sEV lysates, and those
shared between cells and sEVs. When comparing the ESFT
and non-ESFT cell line samples, a similar number of miRNA
(456 and 498, respectively) were detected in cells but not in
their corresponding sEVs (Figure 2A and B). In contrast,
nearly half (49%), of the miRNA produced in ESFT cells were
also found enriched within their corresponding sEVs (440 out
of 896 miRNAs), while only a little over a quarter (~30%) of
the total non-ESFT miRNAs were identified in their sEVs
(228 out of 726 miRNAs) (Figure 2A and B).

Silencing of EWS-FLI1 impacts the enrichment of
sEV miRNAs
We next questioned whether the EWS-ETS oncoprotein was
contributing toward the increased exo-miRNA enrichment in
ESFT. To examine this possibility we generated 3 ESFT cell
lines with Dox-inducible FLI1 shRNA or a non-targeting
shRNA (sc).20 Two cell lines from the original sequencing (TC32 and SK-ES) representing Types I and II fusions were used. In
addition, we utilized the ESFT cell line, A673 which was established from a patient diagnosed with primary rhabdomyosarcoma
and later was found to contain the EWS-FLI1 fusion pathognomonic for ESFT.21 Importantly, A673 has been found to be less
dependent on the EWS-FLI1 oncoprotein for survival and
responds well to EWS-FLI1 knock down. Knock-down of
EWS-FLI1 had varying but consistent results on each of the 3
cell lines. In each case, cells were treated with doxycycline in
48-hour intervals with sEVs and cells harvested at the 48-hour
mark. Regardless of cell line, the knock-down of cellular EWSETS oncoprotein resulted in decreased miRNA enrichment
within sEVs and an increased number of miRNAs identified in
the cell in comparison to samples treated with a non-targeted
shRNA (Figure 3A–F). While preliminary, these data are interesting and suggestive that the EWS-FL1 oncoprotein potentially
contributes to miRNA loading and enrichment into sEVs.

6
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Figure 1. ESFT sEVs are enriched in miRNAs. (A and B) The average number of individual miRNAs found within ESFT cell lines (black bars) was higher,
although not significantly, as compared to the Non-ESFT cell lines (gray bars). (C and D) The average number of individual miRNAs was found to be
2-fold, significantly higher, in ESFT sEVs (black bars) compared to Non-ESFT samples (gray bars). (E) Total ng of DNA between ESFT and Non-ESFT
sEV samples.

Lastly, we asked which miRNAs were produced by all cell
lines (ESFT and non-ESFT) but were at levels only detectable
in ESFT cells-derived sEVs (Supplemental Figure 3A). We
identified 369 miRNAs which were commonly expressed in
75% of cell lines (at least in 3 out of 4 non-ESFT and in 6 out
of 8 ESFT cell lines) (Supplemental Figure 3B). We then compared these miRNAs with the list of 125 exo—miRNA which
were identified in ESFT-derived but not in non-ESFTderived sEVs (Supplemental Figure 3B). Of these, 89 exomiRNA were identified as enriched in ESFT sEVs. Analysis of

the expression levels in the parental cells provided some indications as to why these miRNAs are primarily enriched within
ESFT sEVs. Around 51 out of the 89 had at least a greater
than 2-fold increase in expression within ESFT cells as compared to non-ESFT cells, suggesting that perhaps this group of
miRNAs are sorted into sEVs simply because they are more
abundantly expressed in their parental cell. Surprisingly, 38 of
the miRNAs had similar or even lower (<2-fold) expression
within ESFT as compared to non-ESFT, suggestive of a more
regulated mechanism of intracellular miRNA sorting.
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Figure 2. miRNA localization. (A, B) Number of miRNAs identified only within sEVs, cells, or within both cell and corresponding sEVs. (A) 8 ESFT
samples. (B) 4 Non-ESFT samples.

Identification of an ESFT exo-miRNA signature
Given the enrichment of miRNA within ESFT sEVs, we
next questioned if ESFT sEVs harbored exo-miRNAs which
would serve as a liquid-based disease-specific ESFT biomarker panel. To accomplish this, the results from miRNAseq
data were evaluated by pair-wise analysis to determine differential enrichment of miRNAs between ESFT sEVs and
non-ESFT sEVs. In addition, we also ran the same analysis
on the parental cell lines. Of these, we identified exo-miRNAs with an absolute logFC > 2, and an FDR of <0.1
(Figure 4A and B and Supplemental Data Files). In comparing the sEV signatures, we identified 62 exo-miRNAs predicted to be significantly differentially sorted between ESFT
and non-ESFT sEV samples (P < .05) (Figure 4B and C). Of
these, 41 exo-miRNAs were enriched in ESFT samples and
21 were enriched in non-ESFT samples (Figure 4C). To
determine if these results could be validated using different
technologies, we evaluated matched samples using the
Nanostring miRNA V3 panel which determines counts of
800 miRNAs and by qPCR using pre-designed TaqMan
probes. Importantly, we were able to confirm that most of the
miRNAs uncovered by NGS were also found using these
complementary methods, including miRNAs with the most
significant differential enrichment, for example, miR-140-3p
and miR-100-5p (Figure 4D–I and Supplemental Figure 4).
Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis (performed by miRPath V.3)22 of the 62 exo-miRNAs,
highlighted significant involvement in many tumor-associated pathways known to be involved in ESFT including;
PI3K-AKT/mTOR,23 IGF1R,24 and TGF-beta signaling25
(Supplemental Table 1).

Plasma-derived exo-miRNA can be used to identify
ESFT patients from controls
We next evaluated the diagnostic potential of the 62 exo—
miRNA panel to distinguish ESFT patients from

non-ESFT patients using sEVs isolated from 500 µL of
plasma. Total RNA was isolated from plasma-derived sEVs
from 5 pediatric ESFT patients (prior to therapy), 4 noncancer pediatric patients, 2 pediatric rhabdomyosarcoma
patients (prior to therapy), and 2 pediatric osteosarcoma
patients (prior to therapy) (Figure 5A). The sEV total RNA
was sequenced in the same manner as the cell line derived
sEVs. Upon quantifying the individual miRNAs identified
within these clinical samples we observed that like our in
vitro results, the ESFT patients had nearly a 3-fold increase
in miRNAs than any of the control groups with an average of
275 exo-miRNAs identified in ESFT pediatric patients and
<100 exo-miRNAs identified in pediatric non-cancer, rhabdomyosarcoma, and osteosarcoma samples (Figure 5B). We
next evaluated the enrichment pattern of the previously
identified 62 exo-miRNAs within these clinical samples.
Around 46 out of 62 miRNAs were at detectable levels in
plasma-derived sEVs. Using these 46 miRNAs we were able
to correctly classify 4 out of the 5 ESFT patient samples
using total sEVs from plasma sample (Figure 5C). One osteosarcoma sample clustered more closely with the ESFT
samples and was considered a false positive.
Given the small sample set of this preliminary study we further tested the 46 exo-miRNAs identified within the clinical
samples. We took the 46 miRNAs and performed an unsupervised model-based clustering of the data using a finite mixture
of Gaussian distributions and assuming 2 clusters. The results
showed that 11/13 samples were correctly clustered. The 2 outliers, PT 7 (ESFT) and PT 30 (osteosarcoma) which was consistent with the results in Figure 5. The rand index, a measure
of cluster similarity, was 0.72. The rand index ranges from =0
(no similarity between the true class label and the clustering
result) to =1 (the class labels and the clustering result are perfectly in sync) and can be thought of as a measure of accuracy.
To further evaluate the predictive power of these 46 exo-miRNAs we next randomly selected 46 miRNAs from the total
sequencing results and computed the rand index between the
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Figure 3. Knock-down of EWS-ETS leads to decreases in sEV-miRNAs. (A–F) Western blots (A, C and E) and corresponding miRNA expression profiles
(B, D and F) of 3 ESFT cell lines treated with tet-inducible FLI1 targeting or non-targeting shRNAs. (G) % of total identified miRNAs in sEVs.
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Figure 4. Identification of an ESFT sEV-miRNA signature. (A and B) Volcano plots depicting miRNA with significant enrichment in (A) cells and (B) sEVs.
miRNAs above the black horizontal line are significant (uncorrected P < .05), red dots signify genes with false discovery rate of <0.1. The 2 vertical lines
denote log fold change of 2 (right) or −2 (left). (C) Heat map of Pearson clustering of the 63 candidate miRNAs. (D–I) Results from matched samples run
on the Nanostring Human MiRNA V3 panel (E, H) and biological triplicates run by qPCR (F, I) were compared to miRNAseq results (D, G). Two miRNAs
with P < .05 and an FDR of <0.1.
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Figure 5. Identification of ESFT patients through sEV miRNA signatures. (A) Schematic of total RNA isolation from plasma sEVs. (B) Number of
individual miRNAs identified in clinical plasma sEV samples. (C) Pearson’s clustering of clinical miRNA samples using the 62 miRNA biomarker panel.
Box indicates 4 out of the 5 ESFT patients were correctly classified as ESFT.

resulting clustering and the true class labels. This process was
repeated 1000 times and generated a distribution of rand indices for randomly selected sets of 46 miRNAs. Our results
showed that the rand index obtained the identified 46 miRNAs was as large or larger than the rand index obtained from
random sets of 46 miRNAs 97.7% of the time. Thus, our

exo-miRNA fingerprint leads to a clustering solution that is
more reflective of the true underlying status of the sample
(ESFT vs non-ESFT) than random miRNA groupings. While
these results are intriguing, they will need to be further validated in a collaborative study considering the small sample set
given the rarity of the disease. Nevertheless, the finding
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reported do provide evidence that exo-miRNAs can be used in
a liquid-based biopsy assay to help confirm the diagnosis of
pediatric ESFT.

Identification of a novel EWS-FLI1 fusion
transcript
Despite the small number of clinical samples in this evaluation set we observed that one ESFT patient (PT 7) was
consistently misidentified. This specific case did not exhibit
the increase in the number of miRNA sorted into sEVs
(Figure 5B—blue dot) and clustered more strongly with the
pediatric rhabdomyosarcoma cases than with pediatric
ESFT cases (Figure 5C). Upon further analysis we discovered that this patient’s tumor did not display the high CD99
membranous levels which is a clinical characteristic of
ESFT. In fact, in a published study conducted in tandem
with this analysis, PT 7 is the only ESFT patient out of 12
samples, to have a CD99 immunohistochemical score of
“moderate” by a trained pathologist, while the 11 others
tumor samples were ranked as “high.”26 Despite this finding,
radiographic imaging including PET, along with both clinical and pathologic findings were all consistent with the
diagnosis of localized osseous Ewing Sarcoma of the extremity as well demonstrated presence of EWSR1 breakage as
determined by FISH (Figure 6A–C). Given the high promiscuity of EWSR1 in fusion genes and fusion oncoproteins
in a variety of malignancies outside of ESFT, we questioned
whether this patient may have an alternative EWSR1 binding partner atypical of ESFT. To date, only 12 forms of the
EWS-FLI1 transcript have been reported with EWS-FLI1
fusion types I, II, and III being involved in over 90% of
cases.27-29 Next generation sequencing using a RNA/DNA
multimodal panel of the tumor biopsy for PT 7 revealed a
previously undefined EWS-FLI1 genomic rearrangement
composed of exons 1 to 10 of the EWSR1 gene and exons 7
to 9 of FLI1, (EWSR1{NM_013986.4}:r.1_1096_
FLI1{NM_002017.5}z:r.909_3825) (Figure 6D and E).

Discussion

The ability for both diagnostic identification and monitoring
of disease, especially those with arbitrary and non-specific
symptoms can be the key toward improved overall outcomes
for sarcomas. For pediatric malignancies, this becomes even
more imperative given the rarity of disease, the often-vague
and non-specific clinical symptoms on initial presentation,
and the magnitude of therapy-induced long-term adverse
effects. In this study we have developed a miRNA disease signature from ESFT cell line-derived sEVs. We focused on the
miRNA content of ESFT sEVs for 2 reasons. As described
previously in the introduction, the EWS-ETS oncoprotein
has been implicated and shown to be directly involved miRNA
regulation in both the nucleus and the cytoplasm. Secondly,
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previous studies indicate that, while longer RNA fragments
can be found within sEVs, most sEV RNA content falls within
the small, <40 nt range.30 Importantly, we chose to focus on
sEV-derived miRNA due to the protective nature of sEVs
themselves and relative ease of isolation from plasma.31
Several studies have shown that ESFT tumor cells contain
unique miRNA profiles.32-35 We found this to also be true for
ESFT derived sEVs; however, we were surprised by the
enrichment of miRNA within correlative ESFT-derived
sEVs. In this work we show for the first time that ESFT
sEVs contain an increased level and number of individual
miRNAs as compared to controls. Surprisingly, this remained
true when evaluating ESFT and non-ESFT plasma-derived
sEVs. The idea that miRNAs are sorted into sEVs in a controlled manner has been described in several cell models such
as breast cancer,36 human embryonic kidney cells,37 colorectal
cancer,38 T and B cells, as well as NK cells.39 While the mechanisms of such a regulated process are still elusive and seem to
be dependent upon the cellular origin, we observed some evidence of this type of regulated sorting within ESFT cells.
Current ideas of the mechanisms of miRNA-sorting include
involvement of the neural sphinglmyelinase2 pathway,40 the
sumoylated heterogeneous nuclear ribonucleoproteins
(hnRN0s) dependent pathway,41 dependence upon uridylation or adenylation of the 3′ ends of miRNAs,42 and an
involvement with an Ago2/KRAS-related pathway.43 Of
these, there is currently no identifiable direct correlation
between ESFT and/or the EWS-ETS oncoprotein and these
mechanisms. In these studies, we provided evidence, by way
of an inducible EWS-ETS shRNA construct that, in 3 independent ESFT cell lines, there is a decrease in number of
miRNAs sorted into sEVs when EWS-FLI1 is silenced. Our
previous work has identified the EWS-FLI1 oncoproteins in
sEVs such as exosomes.26 We suspect that EWS-FLI1 is
important for miRNA enrichment in sEVs however a potential mechanism remains elusive. While this body of work is
focused on biomarker development, future work should investigate potential roles of EWS-ETS in the enrichment of
miRNAs into sEVs.
Of importance we were able to identify a panel of 62 exomiRNAs which were differentially enriched into the sEVs of
ESFT cells as compared to both benign and non-ESFT controls. This report is, to the best of our knowledge, the first
analysis of miRNA content of pediatric ESFT-plasma sEVs.
Recent work by Kosela-Paterczyk et al44 has identified significant differences in circulating miRNAs which can differentiate adult Ewing Sarcoma from other adult sarcomas and
healthy controls. In these studies, 2 miRNAs were identified
with biomarker potential, imiR-142-3p and miR-9-3p. These
data corroborate our results given that we also identified
miR-142-3p as a lead biomarker candidate with a logFC of
1.82 and P < .004. Interestingly, we did not identify

12

Biomarker Insights 

Figure 6. Identification of a previously uncharacterized EWS-FLI1 fusion transcript. (A–C) FISH analysis of the EWSR gene. (D, E) Next generation
sequencing results of the EWS-FLI1 fusion depicting a EWS (exon 10) to FLI1 (exon 7) fusion.

miR- 9-3p, but rather did identify miR-9-5p as a candidate
biomarker with a logFC of 1.62 and P = .37. In addition, we
found that our ESFT cellular results to agree with work done
by Karnuth et al,45. In their work the authors identify a over
30 miRNAs with lower or higher expression levels than mesenchymal stem cells. Of interest, both of our groups identified
has-miR-146b-5p to be highly overexpressed and has-miR31
and has-miR-100 to have decreased expression in ESFT cells
compared to controls.45 The benefit of using a sEV-based liquid biopsy approach (as compared to circulating RNA or
tumor biopsy), is that the basic morphology of the sEV protects delicate cargo, such as miRNAs, and are actively released

from viable cells therefore providing a more “real-time” picture of the active tumor. Rapid advancement of microfluidic
chip development, especially as it pertains to sEV analysis46-48
further emphasizes the potential for the clinical utility of
exo-miRNAs.
In these studies, we were able to correctly classify 80%
(4/5) of ESFT patients using our panel of exo-miRNAs.
Strikingly, this signature could be evaluated from as little as
500 µL of archival patient plasma acquired by a relatively
non-invasive blood draw, and importantly did not require
any pre-enrichment for tumor-specific sEVs. Importantly
100% (4/4) of the healthy controls and 75% (3/4) of
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the non-ESFT sarcoma samples did not show the disease
exo-miRNA signature. Regarding the former, the exomiRNA signature was developed using a panel of ESFT cell
lines representative of the most common EWS-ETS gene
fusions. Our results lead us to question if the outlier might
not be a traditional ESFT tumor. In fact, we discovered a
novel and thus rare EWS-FLI1 gene fusion, consistent clinically with ESFT; however, we speculate that the predicted
mutant fusion oncoprotein might have different activities
related to miRNA processing.
Previous analysis of large cohorts of ESFT samples, such as
the Rizzoli Experience, documented 5 distinct EWS-FLI1
fusion transcripts out of 222 ESFT tumor biopsies.29 We did
note that this fusion lacks FLI1 exon 6 which most distinctly
separates it from the 3 most common EWS-FLI1 fusion transcripts which were also the basis of our discovery sample set.
This discovery also reinforces the heterogeneity of this group
of tumors, each with distinct features and should continue to
be elucidated to identify biomarkers and therapeutic targets for
subsets of this tumor type.

Conclusion

Overall, our data demonstrate for the first time the clinical potential of sEV-derived miRNAs to diagnose and
monitor disease progression for the most common types
of ESF T. While we fully acknowledge that our clinical
sample size is not powered to fully demonstrate the
potential clinical utility of the exo-miRNA disease signature, we expect that future analyses will require a significantly larger cohort of sample f rom patients with this
rare disease to help validate our exo-miRNA-signature.
These future studies will require participating by cooperative groups, for example, Children’s Oncology Group,
to improve upon the overall specificity and sensitivity of
this early-stage diagnostic ESF T biomarker panel
described in the study. With the rapid advancements of
microfluidic chip development, it naturally follows that
interrogation of plasma-derived sEV miRNAs will
become an informative and robust diagnostic tool, especially for patients with tumors that are difficult to biopsy
and image, and in cases of monitoring for disease
reoccurrence.
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